CLN H11.4 (ATCC® HB-8307)

Organism: human (B cell); human (myeloma)  /  Cell Type: hybridoma: B lymphocyte  /  Disease: a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.,a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.

Permits and Restrictions

View Permits

Organism human (B cell); human (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells contain EBV viral nucleic acid sequences
Disease a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.,a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
Applications
The antibody reacted with carcinomas of the cervix (CaSki, HeLa), prostate (PC-3), breast (ZR-76-1), colon (COLO-205) and melanoma (G-361) but was negative for normal fibroblasts (WI-38 and MRC-9), T. lymphocytes and peripheral blood lymphocytes.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Storage Conditions liqid nitrogen vapor temperature
Derivation
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061).
Clinical Data
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Genes Expressed
immunoglobulin; monoclonal antibody; against human cervical carcinoma
Comments
The fusion line, CRL-8061, is reported to be EBNA positive.
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061).
The antibody reacted with carcinomas of the cervix (CaSki, HeLa), prostate (PC-3), breast (ZR-76-1), colon (COLO-205) and melanoma (G-361) but was negative for normal fibroblasts (WI-38 and MRC-9), T. lymphocytes and peripheral blood lymphocytes.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liqid nitrogen vapor temperature
Culture Conditions
Temperature: 37.0°C
Isotype IgG1; kappa light chain; human RefAotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115
Name of Depositor Gildred Cancer Center
References

Handley HH, et al. Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies. US Patent 6,051,387 dated Apr 18 2000

Handley HH, et al. Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions. US Patent 6,051,229 dated Apr 18 2000

Handley HH, et al. CLNH11-specific antibodies. US Patent 6,051,693 dated Apr 18 2000

Hagiwara H, Sato GH. Human X human hybridoma producing monoclonal antibody against autologous cervical carcinoma. Mol. Biol. Med. 1: 245-252, 1983. PubMed: 6334217

Aotsuka Y, Naito M. Enhancing effects of retinoic acid on monoclonal antibody production of human-human hybridomas. Cell. Immunol. 133: 498-505, 1991. PubMed: 2015633

Aotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115

Aotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Handley HH, et al. Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies. US Patent 6,051,387 dated Apr 18 2000

Handley HH, et al. Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions. US Patent 6,051,229 dated Apr 18 2000

Handley HH, et al. CLNH11-specific antibodies. US Patent 6,051,693 dated Apr 18 2000

Hagiwara H, Sato GH. Human X human hybridoma producing monoclonal antibody against autologous cervical carcinoma. Mol. Biol. Med. 1: 245-252, 1983. PubMed: 6334217

Aotsuka Y, Naito M. Enhancing effects of retinoic acid on monoclonal antibody production of human-human hybridomas. Cell. Immunol. 133: 498-505, 1991. PubMed: 2015633

Aotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115

Aotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115